What Intrarosa Treats: Main Uses and Benefits

Intrarosa is a localized prescription therapy used for postmenopausal women to address Vulvar and Vaginal Atrophy (VVA), which is commonly associated with Genitourinary Syndrome of Menopause (GSM). The medication is relevant in clinical settings marked by the discomfort that arises from tissue changes due to hormone decline.

The primary therapeutic applications include the management of moderate to severe painful sexual intercourse (dyspareunia), chronic vaginal dryness, and localized soreness and irritation. Applied in situations where additional symptomatic support is needed, Intrarosa may assist with easing challenging symptoms, which supports comfort during periods of heightened symptoms.

Management of Symptoms and Patient Benefit

This medication helps manage the symptoms that arise from the tissue changes characteristic of VVA, and the overall benefit is to reduce the noticeable physiological strain these symptoms impose on daily functioning. The medication is applied in managing chronic symptoms where supportive relief is considered appropriate.

Quick Fact: Symptomatic Support for Dyspareunia
Primary Symptom Targeted	Painful sexual intercourse (Dyspareunia)
Severity Relevance	Moderate to severe manifestations
Core Therapeutic Benefit	Contributes to improved comfort during sexual activity

Intrarosa (Prasterone) is authorized for use exclusively by postmenopausal women, the sole indicated population. The medicine is not indicated for the pre-menopausal or pediatric populations, as safety and effectiveness have not been established in these groups. Use in women ge 65 years is generally permitted with no necessary dose adjustment.

---

Who Must Not Use Intrarosa (Contraindications)

Official regulatory documents prohibit the use of Intrarosa in women who have:

• Undiagnosed abnormal genital bleeding.
• A history of, known, or suspected breast cancer or other oestrogen-dependent malignant tumours.
• Untreated endometrial hyperplasia.
• Acute liver disease or a history of it where liver function tests have not returned to normal.
• A known hypersensitivity to the active substance or any ingredient.

---

Use Restrictions and Limitations

The medicine is not indicated for use during pregnancy or breastfeeding. While use in geriatric patients is generally permitted, the effects of severe renal or hepatic impairment on the drug's metabolism have not been studied. Close medical supervision is required for women with pre-existing conditions such as leiomyoma, endometriosis, or risk factors for thromboembolic disorders.

Intrarosa Interactions with other medicines and products

Due to its localized route of administration, Intrarosa (Prasterone) is not expected to interfere with the action of most other systemic medicines. Official regulatory information documents a lack of significant interaction with many agents that modulate systemic metabolic pathways, including specific antiviral and antifungal treatments (such as itraconazole, midazolam, and sofosbuvir-based regimens). There are no mandatory timing-based restrictions required for co-administration with food, alcohol, or other oral medications. This pharmacokinetic profile reflects minimal systemic drug exposure.

The official regulatory profile focuses on two primary interaction-related constraints:

Interaction Domain	Official Constraint/Restriction
Pharmacodynamic Overlap	Co-administration with other hormonal treatments (androgens, estrogens, or progestins) is restricted because the safety of such combinations has not been established in clinical trials and are therefore excluded from safety data.
Drug–Device/Substance Interaction	The vaginal insert may cause the weakening of latex-based products, including condoms, diaphragms, and cervical caps. This physical incompatibility is a documented risk for the integrity of these devices.

Interactions with food, alcohol, and herbal products are officially reported as not established and not expected. The overall interaction structure emphasizes the product's local action and the need to avoid combination with other substances that produce overlapping hormonal or physical effects, as defined in regulatory labeling.

Intracrine Steroidogenesis and Dual-Receptor Activation

Prasterone acts as a prohormone, relying on intracrine metabolism by specific steroidogenic enzymes (like hydroxysteroid dehydrogenases and aromatase) present in the vaginal cells. This enzymatic process performs the conversion, transforming the inactive precursor into both androgens (e.g., testosterone) and estrogens (e.g., estradiol), which subsequently bind to their respective Androgen Receptors (AR) and Estrogen Receptors (ER) in the cell nucleus. This localized delivery concentrates the production of active hormones within the target tissue, resulting in minimal systemic exposure.

---

Epithelial Maturation and Local Physiological Modulation

The dual activation of AR and ER modulates gene transcription, initiating a cascade of cellular proliferation and epithelial maturation that increases tissue thickness. This growth also increases the presence of glycogen-rich cells, which, through metabolism by local flora, results in a reduction of vaginal pH. These combined effects result in changes to the tissue structure, including enhanced hydration and elasticity, which are the primary physiological outcomes of the drug's local mechanism.

The administration of Intrarosa (prasterone vaginal insert) follows a standardized protocol. The approved route is intravaginal use, utilizing a 6.5 mg vaginal insert once daily. This regimen establishes a fixed dose and frequency with no instructions for dose titration. The administration is specifically timed to occur at bedtime each night, providing a consistent use pattern.

The insert is administered using the provided applicator or, alternatively, a clean finger. During insertion, the insert should be gently placed into the vagina as far as it can comfortably go without force. If a dose is forgotten, the protocol involves skipping the missed insert if the next scheduled dose is due in less than 8 hours; patients are advised against using two inserts to compensate for a missed dose.

Intrarosa is intended for use exclusively in postmenopausal women. The medication requires no dose adjustment for older adults or for patients with renal or hepatic impairment, due to the drug’s localized action. For duration of therapy, the continuing need for treatment involves re-evaluation by a healthcare professional at least every 6 months to ensure the benefit remains greater than the risk.

Research evidence / Overview of studies for Intrarosa

---

Evidence for Use in Vulvar and Vaginal Atrophy (VVA)

The primary clinical evaluation for Intrarosa involved postmenopausal women who experienced symptoms related to Vulvar and Vaginal Atrophy (VVA). The foundation of this evidence relies on large, multi-center, short-term randomized, double-blind, placebo-controlled Phase 3 clinical trials. These studies were used in research exploring how symptoms change over time when compared directly to a non-active insert (placebo).

The trials included postmenopausal women who identified moderate to severe painful sexual intercourse (dyspareunia) as their most bothersome symptom of VVA. The primary controlled research focused on outcomes observed over a defined time interval of 12 weeks.

Outcomes Measured for Painful Sexual Intercourse (Dyspareunia)

In these pivotal studies, researchers primarily monitored patient-reported outcomes describing perceived discomfort. The research examined the change in the severity score of painful sexual intercourse. Research explored whether a difference in the dyspareunia severity score was recorded in the study group compared to the placebo control over the 12-week duration.

Research on Vaginal Tissue Health and Biomarkers

Beyond symptom reporting, research also examined specific physiological biomarkers related to vaginal tissue health. The studies monitored cellular changes, including the percentage of superficial cells and parabasal cells, which are indicators of tissue structure. Findings described patterns where the percentage of superficial cells was monitored to increase, while the percentage of parabasal cells was monitored to decrease during the study period.

Long-Term Studies and Follow-up Data

The primary efficacy evidence for Intrarosa is based on short-term research, typically lasting 12 weeks. To gather information beyond the primary study duration, subsequent studies evaluated outcomes over longer time intervals. This extended data was derived from open-label, non-comparative follow-up studies extending up to 52 weeks. These long-term studies provided observations over defined time intervals but were conducted as open-label designs and did not compare the medication to a placebo over the entire duration.

What is Still Uncertain About the Research Evidence

Several factors related to the evidence remain uncertain or are limited. Firstly, the follow-up durations were limited in the primary controlled trials, meaning long-term effects are not fully established through comparative research. Secondly, findings related to other VVA symptoms, such as vaginal dryness or irritation, were mixed and did not consistently separate from the placebo control in all initial trials. Comparative evidence against other established local VVA therapies is based on indirect treatment comparisons, where high variability across the studies was noted. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study (Labrie F, et al., 2015)

Common questions about Intrarosa (FAQ)

---

Q: How quickly can I expect Intrarosa to start working?

Official clinical studies examined the effects of Intrarosa over a defined period. The evidence indicates that research explored changes in symptoms over a 12-week period when the medicine was used as directed in the trials. The research focused on changes in the severity of painful sexual intercourse (dyspareunia).

---

Q: Does Intrarosa cause weight gain?

According to official product labeling, weight fluctuation has been reported as a side effect during clinical observation. This information describes group patterns observed during studies, not individual outcomes or predictions.

---

Q: Do I need to abstain from sexual activity when starting Intrarosa?

Regulatory documents do not contain explicit warnings about abstaining from sexual activity when using the insert. The medicine is indicated to address the symptoms of painful sexual intercourse (dyspareunia). However, official warnings do exist regarding the risk that the insert may cause the weakening of latex-based products such as condoms and diaphragms.

---

Q: Is the amount of DHEA in Intrarosa significant?

Intrarosa is a localized vaginal insert of prasterone (DHEA). The official dose is lower than the dosages examined in clinical studies of non-prescription DHEA supplements which are administered systemically (by mouth). This difference is consistent with the drug's design for targeted, localized action.

---

Q: Can I use Intrarosa if I have a history of blood clots?

Official product information states that Intrarosa is contraindicated (restricted from use) in patients with active deep vein thrombosis, pulmonary embolism, or history of these conditions, as well as active arterial thromboembolic disease (e.g., stroke, myocardial infarction), or a history of these conditions.

---

Q: What is the difference between Intrarosa and Osphena?

Intrarosa (prasterone) is classified as a steroid vaginal insert that works via localized hormone conversion in the vaginal cells. Osphena (ospemifene) is an oral tablet classified as a Selective Estrogen-Receptor Modulator (SERM). Both agents are approved for treating moderate to severe painful sexual intercourse (dyspareunia) due to menopausal vaginal atrophy.

---

Q: Is Intrarosa available over the counter?

According to official regulatory status, Intrarosa is a prescription (Rx) medicine. It is not available over-the-counter (OTC) and requires a healthcare professional's prescription.

---

Q: Does Intrarosa help with urinary symptoms?

The official regulatory indication for Intrarosa is limited. It is approved only for treating moderate to severe pain during sexual intercourse (dyspareunia) due to menopausal vaginal atrophy.

---

Q: Are there generic versions of Intrarosa available?

Official drug regulatory resources indicate that there are no generic alternatives of Intrarosa (prasterone) currently available on the market.

---

Q: Are headaches a common side effect of Intrarosa?

Headaches are not listed among the most frequent (Common, or ge 1%) side effects in the official prescribing information. The safety data focuses on effects commonly seen in clinical trials.

---

Q: Can Intrarosa cause dryness in other parts of the body?

Based on the drug's local pharmacological profile, Intrarosa is designed for local action and has minimal systemic absorption. Therefore, the medicine is not expected to cause dryness in other parts of the body.

---

Q: Is it normal to feel a burning sensation when first starting Intrarosa?

Official labeling notes that vaginal irritation at the application site has been reported as a side effect. This finding is included in the product's adverse reaction profile.

---

Q: Does Intrarosa have a black box warning?

The official FDA labeling confirms that Intrarosa does not carry a Black Box Warning. This status is documented in the product's regulatory profile.

---

Q: Can I use Intrarosa if I still have a uterus?

Yes, the product is approved for use in postmenopausal women regardless of whether they have a uterus. However, ongoing safety monitoring is a mandatory requirement. This includes the need for periodic pelvic exams and an evaluation of any undiagnosed, persistent, or recurrent genital bleeding.

Storage and Disposal of Intrarosa (Prasterone) Vaginal Inserts

The storage of Intrarosa is defined by specific temperature requirements. The product must be stored between 41 F to 86 F (5 C to 30 C), and can be kept at room temperature or in the refrigerator. It is a mandatory instruction to not freeze the vaginal inserts.

Requirement	Official Regulatory Mandate
Temperature	Store between 41 F to 86 F (5 C to 30 C). Do not freeze.
Child Safety	Keep out of the sight and reach of children.
Packaging	Do not use after the expiry date (EXP) stated on the carton and blisters.

The medicine should be kept in its original container. All unused medicinal product, including expired inserts and applicators, must be disposed of in accordance with local requirements for medicinal waste.